Free Trial
→ What Elon Musk's Cybercab Reveal Could Mean for Investors (From Brownstone Research) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.44 +0.02 (+4.82%)
As of 11/4/2026 03:00 PM Eastern
Compare

MDNA vs. COV, SCYB, COM, NVH, and HBP

Should you buy Medicenna Therapeutics stock or one of its competitors? Medicenna Therapeutics's main competitors and comparable companies include Covalon Technologies (COV), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Helix BioPharma (HBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Medicenna Therapeutics compare to Covalon Technologies?

Medicenna Therapeutics (TSE:MDNA) and Covalon Technologies (CVE:COV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Covalon Technologies. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Covalon Technologies. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Covalon Technologies'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Covalon Technologies Neutral

Medicenna Therapeutics has a beta of 2.926431, indicating that its stock price is 193% more volatile than the broader market. Comparatively, Covalon Technologies has a beta of 0.939041, indicating that its stock price is 6% less volatile than the broader market.

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Covalon Technologies shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 48.7% of Covalon Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Covalon Technologies has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Covalon TechnologiesC$34.35M3.43C$2.39MC$0.1626.63

Covalon Technologies has a net margin of 12.78% compared to Medicenna Therapeutics' net margin of -533,640.00%. Covalon Technologies' return on equity of 15.04% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Covalon Technologies 12.78%15.04%-3.25%

Summary

Covalon Technologies beats Medicenna Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Scythian Biosciences?

Medicenna Therapeutics (TSE:MDNA) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Scythian Biosciences. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Scythian Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scythian Biosciences has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Scythian Biosciences' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Scythian Biosciences N/A N/A N/A

Summary

Medicenna Therapeutics and Scythian Biosciences tied by winning 3 of the 6 factors compared between the two stocks.

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

138267 (COM.TO) has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. 138267 (COM.TO)'s return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

In the previous week, Medicenna Therapeutics had 1 more articles in the media than 138267 (COM.TO). MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for 138267 (COM.TO). 138267 (COM.TO)'s average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
138267 (COM.TO) Neutral
Medicenna Therapeutics Neutral

Summary

138267 (COM.TO) and Medicenna Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Novoheart?

Novoheart (CVE:NVH) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Novoheart. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Novoheart. Novoheart's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Novoheart Neutral
Medicenna Therapeutics Neutral

Novoheart has higher revenue and earnings than Medicenna Therapeutics. Novoheart is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Novoheart has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Novoheart's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

Summary

Novoheart beats Medicenna Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Helix BioPharma?

Medicenna Therapeutics (TSE:MDNA) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Comparatively, 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Helix BioPharma has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Helix BioPharma's return on equity of -22.23% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Helix BioPharma N/A -22.23%-279.98%

Medicenna Therapeutics has a beta of 2.926431, suggesting that its share price is 193% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 1.391641, suggesting that its share price is 39% more volatile than the broader market.

In the previous week, Helix BioPharma had 3 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 4 mentions for Helix BioPharma and 1 mentions for Medicenna Therapeutics. Helix BioPharma's average media sentiment score of 0.04 beat Medicenna Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medicenna Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Helix BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

Summary

Medicenna Therapeutics beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$40.15MC$4.13BC$7.78BC$13.11B
Dividend YieldN/A3.63%2.48%4.74%
P/E Ratio-1.9832.9135.5230.41
Price / SalesN/A17.238.913.99
Price / Cash1.1526.7621.6734.92
Price / Book22.534.484.833.57
Net Income-C$25.98M-C$22.09MC$3.50BC$299.09M
7 Day Performance-9.38%-1.05%-0.76%-0.45%
1 Month Performance6.10%-7.50%-4.16%-1.64%
1 Year Performance-71.57%5.20%3.39%15.37%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.44
+4.8%		N/A-70.8%C$40.15MN/AN/A20
COV
Covalon Technologies
N/AC$4.43
-0.7%		N/A+97.2%C$122.35MC$34.35M27.69105
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 11/5/2026 by MarketBeat.com Staff.
From Our Partners
The 401k Email 70 Million Investors Might Delete
An email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...
Brownstone Research | Sponsoredtc pixel
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...
Behind the Markets | Sponsoredtc pixel
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...
TradeWins | Sponsoredtc pixel
This little-known fund tracks gold and pays out weekly
A little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...
Investors Alley | Sponsoredtc pixel
$29.97 or $0 today
The 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...
Profits Run | Sponsoredtc pixel